Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-17 11:44 am Purchase | 2025-09-25 | 13G | Cytek Biosciences, Inc. CTKB | Topline Capital Management, LLC | 6,780,847 5.300% | 6,780,847 (New Position) | Filing History |
| 2025-11-12 2:00 pm Sale | 2025-09-30 | 13G | Cytek Biosciences, Inc. CTKB | Brown Capital Management, LLC | 4,958,016 3.900% | -2,505,951 (-33.57%) | Filing History |
| 2025-07-29 11:21 am Sale | 2025-06-30 | 13G | Cytek Biosciences, Inc. CTKB | The Vanguard Group | 7,765,138 6.130% | -1,856,870 (-19.30%) | Filing History |
| 2025-07-18 2:52 pm Sale | 2025-06-30 | 13G | Cytek Biosciences, Inc. CTKB | BlackRock Inc. BLK | 16,531,858 13.100% | -1,950,937 (-10.56%) | Filing History |
| 2025-05-15 2:07 pm Sale | 2025-03-31 | 13G | Cytek Biosciences, Inc. CTKB | Brown Capital Management, LLC | 7,463,967 5.890% | -2,029,507 (-21.38%) | Filing History |
| 2025-04-30 10:57 am Sale | 2025-03-31 | 13G | Cytek Biosciences, Inc. CTKB | The Vanguard Group | 9,622,008 7.510% | -2,268,692 (-19.08%) | Filing History |
| 2025-02-14 6:29 pm Sale | 2024-12-31 | 13G | Cytek Biosciences, Inc. CTKB | RA Capital Management, L.P. | 0 0.000% | -6,809,404 (Position Closed) | Filing History |
| 2025-02-05 1:23 pm Purchase | 2024-12-31 | 13G | Cytek Biosciences, Inc. CTKB | BlackRock Inc. BLK | 18,482,795 14.300% | 703,042 (+3.95%) | Filing History |
| 2024-11-14 4:35 pm Purchase | 2024-09-30 | 13G | Cytek Biosciences, Inc. CTKB | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 6,657,030 5.100% | 6,657,030 (New Position) | Filing History |
| 2024-11-14 1:42 pm Sale | 2024-09-30 | 13G | Cytek Biosciences, Inc. CTKB | Brown Capital Management, LLC | 9,493,474 7.220% | -2,522,851 (-21.00%) | Filing History |
| 2024-02-22 7:07 pm Unchanged | 2023-12-31 | 13G | Cytek Biosciences, Inc. CTKB | RA Capital Management, L.P. | 6,809,404 5.200% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:39 pm Sale | 2023-12-31 | 13G | Cytek Biosciences, Inc. CTKB | HHLR ADVISORS LTD. | 6,657,030 4.900% | -2,027,500 (-23.35%) | Filing History |
| 2024-02-14 4:08 pm Sale | 2023-12-31 | 13G | Cytek Biosciences, Inc. CTKB | Yan Ming | 6,203,867 4.700% | -1,999,491 (-24.37%) | Filing History |
| 2024-02-14 4:07 pm Sale | 2023-12-31 | 13G | Cytek Biosciences, Inc. CTKB | Jiang Wenbin | 5,702,130 4.300% | -2,318,353 (-28.91%) | Filing History |
| 2024-02-14 3:12 pm Purchase | 2023-12-31 | 13G | Cytek Biosciences, Inc. CTKB | Brown Capital Management, LLC | 12,016,325 8.860% | 12,016,325 (New Position) | Filing History |
| 2024-02-13 5:02 pm Purchase | 2023-12-29 | 13G | Cytek Biosciences, Inc. CTKB | The Vanguard Group | 11,890,700 8.770% | 4,119,633 (+53.01%) | Filing History |
| 2024-01-23 4:13 pm Purchase | 2023-12-31 | 13G | Cytek Biosciences, Inc. CTKB | BlackRock Inc. BLK | 17,779,753 13.100% | 2,944,538 (+19.85%) | Filing History |
| 2023-09-19 5:25 pm Sale | 2023-09-15 | 13D | Cytek Biosciences, Inc. CTKB | RA Capital Management, L.P. | 6,809,404 4.990% | -6,329,923 (-48.18%) | Filing History |
| 2023-05-05 11:52 am Purchase | 2023-04-30 | 13G | Cytek Biosciences, Inc. CTKB | BlackRock Inc. BLK | 14,835,215 10.900% | 6,467,608 (+77.29%) | Filing History |
| 2023-02-14 4:09 pm Sale | 2022-12-31 | 13G | Cytek Biosciences, Inc. CTKB | HHLR ADVISORS LTD. | 8,684,530 6.400% | -72,500 (-0.83%) | Filing History |